The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma. The biotech has now gone under.
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A.
Basis announced the appointment of Kenji Kuramoto, founder of Acuity, which last year merged with thirteen other firms to form top 50 firm Sorren after he led it for 20 years, as its managing partner in residence.
While AI controls are important, organizations should not pursue one-size-fits-all blanket applications, especially when differentiating between what is a matter of governance versus technology.